文献速递浆细胞疾病

基于临床与基因表达数据的机器学习模型预测多发性骨髓瘤生存并优化治疗

Survival prediction and treatment optimization of multiple myeloma patients using machine-learning models based on clinical and gene expression data.
PubMed 文献 · Leukemia · 2021-05-18

该研究利用CoMMpass联盟收集的多发性骨髓瘤临床与RNAseq数据,构建了含50个变量的随机森林模型(IAC-50),在训练集和验证集中预测总生存的c-index分别为0.818和0.780。模型纳入年龄、ISS分期、血清β2微球蛋白、一线治疗方案及46个基因表达。按最佳预测药物组合治疗的患者死亡风险显著更低,尤其在三药联合方案中。

要点

  • IAC-50模型整合临床、生化与基因表达数据,训练集c-index 0.818,验证集0.780。
  • 模型变量包括年龄、ISS分期、血清β2微球蛋白、一线治疗及46个基因表达。
  • 按模型预测最佳药物组合治疗的患者死亡风险显著更低,尤以硼替佐米+免疫调节剂+地塞米松三联方案为著。

核心结论

  • 基于临床、生化与基因表达数据结合机器学习可构建多发性骨髓瘤生存预测模型。
  • 按模型预测的最佳药物组合治疗与更低死亡风险相关。

研究设计与样本

  • 应用机器学习算法分析CoMMpass联盟收集的多发性骨髓瘤临床与RNAseq数据。
  • 构建了含50个变量的随机森林模型(IAC-50),并在训练集与验证集中评估。

主要发现

  • IAC-50模型预测总生存的c-index在训练集为0.818,验证集为0.780。
  • 模型纳入年龄、ISS分期、血清β2微球蛋白、一线治疗及46个基因表达。
  • 按最佳预测药物组合治疗的患者死亡风险显著低于其他方案治疗者。
  • 该差异在含硼替佐米、免疫调节剂和地塞米松的三联方案患者中尤为重要。
  • 模型在高危细胞遗传学患者中显示出保留预测价值的趋势。

临床怎么用

  • 可基于患者年龄、ISS分期、血清β2微球蛋白、基因表达及拟用一线方案进行生存预测。
  • 模型预测的最佳药物组合可作为一线治疗选择的参考,尤其涉及含硼替佐米、免疫调节剂和地塞米松的三联方案。

局限性

  • 原文未明确报告模型在高危细胞遗传学患者中的预测价值仅显示趋势。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multiple myeloma (MM) remains mostly an incurable disease with a heterogeneous clinical evolution. Despite the availability of several prognostic scores, substantial room for improvement still exists. Promising results have been obtained by integrating clinical and biochemical data with gene expression profiling (GEP). In this report, we applied machine learning algorithms to MM clinical and RNAseq data collected by the CoMMpass consortium. We created a 50-variable random forests model (IAC-50) that could predict overall survival with high concordance between both training and validation sets (c-indexes, 0.818 and 0.780). This model included the following covariates: patient age, ISS stage, serum B2-microglobulin, first-line treatment, and the expression of 46 genes. Survival predictions for each patient considering the first line of treatment evidenced that those individuals treated with the best-predicted drug combination were significantly less likely to die than patients treated with other schemes. This was particularly important among patients treated with a triplet combination including bortezomib, an immunomodulatory drug (ImiD), and dexamethasone. Finally, the model showed a trend to retain its predictive value in patients with high-risk cytogenetics. In conclusion, we report a predictive model for MM survival based on the integration of clinical, biochemical, and gene expression data with machine learning tools.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Mosquera Orgueira A, González Pérez MS, Díaz Arias JÁ, et al. Survival prediction and treatment optimization of multiple myeloma patients using machine-learning models based on clinical and gene expression data. Leukemia. 2021. PMID: 34007046. doi:10.1038/s41375-021-01286-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。